Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Unraveling Metastasis Drivers in Small Cell Lung Cancer via Human Pluripotent Stem Cell-Based Approach

Award Number: R21CA299377
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2025
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Unraveling Metastasis Drivers in Small Cell Lung Cancer via Human Pluripotent Stem Cell-Based Approach - SUMMARY Small cell lung cancer (SCLC) is among the most lethal malignancies, noted for its pronounced metastatic potential across solid tumors, yet the underlying mechanisms of its metastasis remain largely unknown. In this project, we aim to deploy innovative methods and tools to delve into the longstanding enigmas of SCLC metastasis, leveraging advances in technology to gain clearer insights into this complex issue. We recently developed a method to generate functionally viable pulmonary neuroendocrine cells (PNECs) from human pluripotent stem cells (hPSCs). These cells, as the putative cell of origin of SCLC, can be transformed oncogenically by inducing mutations in key SCLC genes—RB1, TP53, and MYC—resulting in tumor formation in mice that closely resembles clinical SCLC. These modified PNECs effectively replicate the critical stages of SCLC, from tumor initiation to metastatic spread, providing a robust model to investigate the cellular and molecular drivers behind the disease’s aggressive metastasis. Our research strategy integrates hPSC-derived SCLC models, clinical samples, patient-derived xenografts (PDX), and state-of-the-art technologies such as single-cell sequencing and ATAC-seq. By examining cell behavior in both primary tumors and metastatic sites, we propose to uncover essential insights into the metastatic cellular and molecular drivers of SCLC. The outcomes of this research are anticipated to shed light on why SCLC aggressively metastasizes and could lead to novel diagnostic and therapeutic approaches for this formidable cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $191,675 )
2026	2026	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Detection and Diagnosis Research	000	2	3/5/2026	NON-COMPETING CONTINUATION	$191,675
														Subtotal = $191,675

Issue Date FY: 2025 ( Subtotal = $230,010 )
2025	2025	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Detection and Diagnosis Research	000	1	1/30/2025	NEW	$230,010
2025	2025	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Detection and Diagnosis Research	001	1	2/12/2025	NEW	$0
														Subtotal = $230,010

Grand Total All Awards = $421,685

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Unraveling Metastasis Drivers in Small Cell Lung Cancer via Human Pluripotent Stem Cell-Based Approach

Award Number: R21CA299377

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2025

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer